Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Operating Expenses: 2013-2025

Historic Operating Expenses for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $24.4 million.

  • Fortress Biotech's Operating Expenses fell 33.44% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year decrease of 9.98%. This contributed to the annual value of $168.1 million for FY2024, which is 25.92% down from last year.
  • As of Q3 2025, Fortress Biotech's Operating Expenses stood at $24.4 million, which was down 53.78% from $52.9 million recorded in Q2 2025.
  • Fortress Biotech's Operating Expenses' 5-year high stood at $80.3 million during Q4 2021, with a 5-year trough of $24.4 million in Q3 2025.
  • For the 3-year period, Fortress Biotech's Operating Expenses averaged around $46.1 million, with its median value being $42.7 million (2024).
  • In the last 5 years, Fortress Biotech's Operating Expenses skyrocketed by 118.37% in 2021 and then crashed by 44.31% in 2023.
  • Fortress Biotech's Operating Expenses (Quarterly) stood at $80.3 million in 2021, then decreased by 11.51% to $71.0 million in 2022, then slumped by 44.31% to $39.6 million in 2023, then decreased by 1.53% to $39.0 million in 2024, then plummeted by 33.44% to $24.4 million in 2025.
  • Its Operating Expenses was $24.4 million in Q3 2025, compared to $52.9 million in Q2 2025 and $35.5 million in Q1 2025.